Navigate all the latest information in acute lymphoblastic leukemia, arranged by experts and healthcare professionals. Listed below are recently added expert opinions.
Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...
What is new in CAR T-cell therapy for ALL?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv...
When would you favor haploidentical HSCT in ALL?
Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two...
What is new for CAR T-cell therapy for adult patients with ALL?
During the 3rd European CAR T-cell Meeting, the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new...
When should we consider allo-HSCT in a patient with ALL? And when not?
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel,...
How do constitutively active signaling pathways impact response to treatment in pediatric T-ALL?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke...
Interfant-06 study: Why should we assess end-of-consolidation MRD in infants with ALL?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Janine...
Alessandro M. Vannucchi
Marlise R. Luskin
Nicholas J. Short